Login to Your Account


With its first biosimilar stumbling in the murky backstreets of the U.S. biopharma market, Pfizer Inc. is asking a federal court to make Johnson & Johnson (J&J) play by the rules.

The Senate Finance Committee hearing on corporate tax reform included the usual discussion about the high tax rate imposed on companies in the U.S.

The FDA triggered another biosimilar first Thursday with its right-on-schedule approval of Amgen Inc.'s Mvasi.

More U.S. Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: